| Prev Close | 10.05 |
| Day Low/High | 9.04 / 10.69 |
| 52 Wk Low/High | 9.88 / 53.69 |
Pacific Biosciences of California, Inc. (PACB)
10.67
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 220.60B |
| Market Cap | 2.22B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Here Is Something Cathie Wood and I Agree On
* The attractiveness of Coinbase Speaking of ARK Invest, the ETF complex has purchased Coinbase on nearly three-quarters of the days it has been public. All transactions below are dated May 20: FUND Direction Ticker CUSIP Name Shares % of ETF ARKF ...
Pacific Biosciences Reaches Our Price Target: Now What?
Let's check out the charts and technical indicators.
Watch Out, Pacific Biosciences Stock Is Very Extended
This candlestick pattern is very successful in catching significant tops.
Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers
The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.
Illumina Shares Hammered by Sales Forecast Cut
Cantor Fitzgerald says Illumina's outlook revision is not likely to affect industry peers.
This Bounce Could Keep Going
Despite the tepid open, I'm participating with a position in SSO and PACB's chart still looks good.
Stick To Index and Large-Cap Plays
The gap-up open quickly faded, and there is no buying traction at all, right now.
Rev Forum: Make the Market Prove Itself
A strong open doesn't always produce greater clarity.
Tough to Find Individual Stocks I Like
Indices are the way so far in today's challenging market.
You Can't Blame It All on the Fed
There are a number of forces at play in market carnage.
Illumina Dims, but It's Still Set Up to Shine
With such a commanding lead in the sequencing business the stock can't stay down for long.
Budget, Fannie-Freddie Reform Could Boost Defense, Medical, Housing
Washington will offer mixed bag answers to key policy questions.
Opening Up My Watch List
Four small-caps I have an eye on.
The Market Caved
But how long will it last?
